Oaktree Acquisition Corp. II (OACB) to Combine with Alvotech in $2.25Bn Deal

Dec 7, 2021 INTEL by Nicholas Alan Clayton

Oaktree II (NYSE:OACB) has entered into a definitive agreement to combine with biopharma company Alvotech at an enterprise value of $2.25 billion, or 4.6x its 2025E EBITDA. Reykjavik, Iceland-based Alvotech is developing medicines that are biosimilar to branded pharmaceuticals on the market, potentially providing them to the market at lower prices. The combined company is
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.

Oaktree Acquisition Corp. II (OACB) to Combine with Alvotech in $2.25Bn Deal

Oaktree Acquisition Corp. II (OACB) to Combine with Alvotech in $2.25Bn Deal

ByNicholas Alan Clayton